JP2010526807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526807A5 JP2010526807A5 JP2010507419A JP2010507419A JP2010526807A5 JP 2010526807 A5 JP2010526807 A5 JP 2010526807A5 JP 2010507419 A JP2010507419 A JP 2010507419A JP 2010507419 A JP2010507419 A JP 2010507419A JP 2010526807 A5 JP2010526807 A5 JP 2010526807A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- halogens
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92794907P | 2007-05-07 | 2007-05-07 | |
| PCT/US2008/005726 WO2008137105A1 (en) | 2007-05-07 | 2008-05-02 | Method of treatment using fused aromatic compounds having anti-diabetic activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014002247A Division JP2014088424A (ja) | 2007-05-07 | 2014-01-09 | 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010526807A JP2010526807A (ja) | 2010-08-05 |
| JP2010526807A5 true JP2010526807A5 (cg-RX-API-DMAC7.html) | 2011-05-26 |
Family
ID=39943845
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507419A Pending JP2010526807A (ja) | 2007-05-07 | 2008-05-02 | 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法 |
| JP2014002247A Pending JP2014088424A (ja) | 2007-05-07 | 2014-01-09 | 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法 |
| JP2015145891A Pending JP2015227359A (ja) | 2007-05-07 | 2015-07-23 | 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014002247A Pending JP2014088424A (ja) | 2007-05-07 | 2014-01-09 | 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法 |
| JP2015145891A Pending JP2015227359A (ja) | 2007-05-07 | 2015-07-23 | 抗糖尿病活性を有する縮合芳香族化合物を用いた治療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8338458B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2155187B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2010526807A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008248186B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2688187C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008137105A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013068486A1 (en) | 2011-11-08 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of male infertility |
| US9440952B2 (en) | 2013-03-04 | 2016-09-13 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2014134776A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2014134772A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2014134774A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| RU2751341C2 (ru) | 2016-05-26 | 2021-07-13 | РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС | Соединения-ингибиторы egfr |
| US11311542B2 (en) | 2018-01-16 | 2022-04-26 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin dependent kinase 7 (CDK7) |
| EP3740206B1 (en) | 2018-01-16 | 2024-03-06 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| EP3873462A4 (en) | 2018-11-01 | 2022-08-03 | Syros Pharmaceuticals, Inc. | CANCER TREATMENT METHODS IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLINE-DEPENDENT KINASE 7 (CDK7) |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| US12264149B2 (en) | 2020-12-30 | 2025-04-01 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| EP0882029B1 (en) | 1996-02-02 | 2003-04-02 | Merck & Co., Inc. | Heterocyclic derivatives as antidiabetic and antiobesity agents |
| AU1215701A (en) | 1999-10-22 | 2001-05-08 | Merck & Co., Inc. | Pharmaceuticals for treating obesity |
| AU784722B2 (en) | 2000-02-18 | 2006-06-01 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| JP2004513076A (ja) | 2000-07-25 | 2004-04-30 | メルク エンド カムパニー インコーポレーテッド | 糖尿病治療で有用なｎ−置換インドール類 |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| BR0206831A (pt) | 2001-02-02 | 2004-07-06 | Takeda Chemical Industries Ltd | Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto |
| JP2004521124A (ja) | 2001-02-09 | 2004-07-15 | メルク エンド カムパニー インコーポレーテッド | 糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類 |
| ATE395912T1 (de) | 2001-03-27 | 2008-06-15 | Merck & Co Inc | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ES2257555T3 (es) | 2001-06-20 | 2006-08-01 | MERCK & CO., INC. | Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes. |
| AU2002344820B2 (en) | 2001-06-20 | 2006-12-14 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| ES2296979T3 (es) | 2001-06-27 | 2008-05-01 | Smithkline Beecham Corporation | Fluoropirrolidinas como inhibidores de dipeptidil peptidasa. |
| ATE380175T1 (de) | 2001-06-27 | 2007-12-15 | Smithkline Beecham Corp | Pyrrolidine als dipeptidyl peptidase inhibitoren |
| WO2003002553A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| CA2419888A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| WO2003004496A1 (en) | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| ES2259736T3 (es) | 2001-12-21 | 2006-10-16 | Smithkline Beecham Corporation | Regimen de dosificacion para activadores de ppar-gamma-. |
| DE60316416T2 (de) | 2002-03-25 | 2008-06-26 | Merck & Co., Inc. | Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes |
| DE60330485D1 (de) | 2002-07-15 | 2010-01-21 | Merck & Co Inc | Zur behandlung von diabetes |
| TW200404060A (en) | 2002-08-08 | 2004-03-16 | Takeda Chemical Industries Ltd | Fused heterocyclic compounds |
| EP1546142A4 (en) | 2002-08-29 | 2007-10-17 | Merck & Co Inc | INDOLES HAVING ANTIDIABETIC EFFECT |
| PT1537078E (pt) | 2002-08-29 | 2010-06-18 | Merck Sharp & Dohme | Indoles que possuem actividade antidiabética |
| EP1554280B1 (en) | 2002-10-07 | 2007-08-15 | Merck & Co., Inc. | Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors |
| ATE390416T1 (de) | 2002-10-18 | 2008-04-15 | Merck & Co Inc | Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes |
| AU2003290577B2 (en) | 2002-11-07 | 2008-12-11 | Merck Sharp & Dohme Corp. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| EP1737811B1 (en) | 2004-04-13 | 2016-08-10 | Merck Sharp & Dohme Corp. | Cetp inhibitors |
| DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| CA2581072A1 (en) | 2004-09-16 | 2006-03-30 | Merck & Co., Inc. | Compounds for the treatment of dyslipidemia and other lipid disorders |
| CN103102303B (zh) | 2004-12-31 | 2015-10-28 | 雷迪博士实验室有限公司 | 作为cetp抑制剂的苄胺衍生物 |
| TW200640453A (en) * | 2005-01-28 | 2006-12-01 | Lilly Co Eli | Formulations and dosing regimen for PPAR-α modulators |
| CA2598725C (en) * | 2005-03-04 | 2010-10-26 | Merck & Co., Inc. | Fused aromatic compounds having anti-diabetic activity |
| CA2599710A1 (en) | 2005-03-10 | 2006-09-21 | Merck & Co., Inc. | Novel crystalline forms of antidiabetic compounds |
-
2008
- 2008-05-02 US US12/597,530 patent/US8338458B2/en not_active Expired - Fee Related
- 2008-05-02 AU AU2008248186A patent/AU2008248186B2/en not_active Ceased
- 2008-05-02 WO PCT/US2008/005726 patent/WO2008137105A1/en not_active Ceased
- 2008-05-02 EP EP08767538.5A patent/EP2155187B1/en not_active Not-in-force
- 2008-05-02 CA CA2688187A patent/CA2688187C/en not_active Expired - Fee Related
- 2008-05-02 JP JP2010507419A patent/JP2010526807A/ja active Pending
-
2014
- 2014-01-09 JP JP2014002247A patent/JP2014088424A/ja active Pending
-
2015
- 2015-07-23 JP JP2015145891A patent/JP2015227359A/ja active Pending